82
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Cytotoxic oxindole derivatives: in vitro EGFR inhibition, pharmacophore modeling, 3D-QSAR and molecular dynamics studies

&
Pages 460-469 | Received 05 Sep 2019, Accepted 07 Oct 2019, Published online: 09 Dec 2019
 

Abstract

Epidermal growth factor receptor (EGFR) is one of the vital protein targets in many solid tumors and is an attractive target for developing new drugs. In this study we have focused on elucidation of the mechanistic insights of cytotoxic potentials of oxindole derivatives using various in vitro and molecular modeling techniques. In vitro EGFR inhibition assay is performed with the potent cytotoxic oxindole compounds which are previously proved for their cytotoxic activity against breast cancer (MCF7) and ovarian cancer (SKVO3) cell lines. Molecular docking studies against kinase domain of EGFR protein revealed the probable interactions of oxindole derivatives. Pharmacophore modeling studies had identified a pharmacophore model with three hydrogen bond acceptors and three aromatic rings (AAARRR.1003) as a potential model for cytotoxic activity against MCF7 cell lines and validated through 3D QSAR studies resulting in superior regression scores (r2 = 0.92, q2 = 0.80 and Pearson R = 0.95). Molecular dynamic studies have revealed the conformational changes in the EGFR-compound 2complex during the 25 ns simulation time frame.

Acknowledgements

The authors thank Dr Sunil Misra (senior scientist, Biology Division, CSIR-IICT, Hyderabad) for providing biological laboratory facilities to perform biological evaluation. The authors also thank Mrs Swetha and Mr Devender (Discovery Labs, CSIR-IICT, Hyderabad), for providing facilities to perform chemical reactions. We would like to acknowledge Mr Reddy G (ddlabs.in, Hyderabad), for writing assistance and editorial support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.